Last checked at 12 Nov 2021 07:33
12 November 2021
Roquefort Investments plc
("Roquefort Investments" or the "Company")
Update on Acquisition of Lyramid Limited
Roquefort Investments (LSE:ROQ), the London listed investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, is pleased to announce that it has commenced marketing to potential investors to fund the acquisition and pre-clinical drug development programme of Lyramid Limited, details of which were announced on 29 September 2021. A copy of the presentation is available on the Company's website at https://www.roquefortinvest.com/presentations
The Company looks forward to providing further updates in relation to the acquisition of Lyramid Limited as and when appropriate.
The Company's shares remain suspended from trading on the Main Market of the London Stock Exchange pending the publication of a Prospectus setting out full details of the potential transaction.
Enquiries:
Roquefort Investments plc | |
Stephen West (Chairman) | +44 (0)20 3290 9339 |
Optiva Securities Limited (Joint Broker) | |
Christian Dennis | +44 (0)20 3411 1881 |
For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.
LEI: 254900P4SISIWOR9RH34